Maine Biotechnology Services brings 25 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved, MBS has risen to the challenge to effectively meet those needs.
The cornerstone of antibody and assay development at MBS is our technical team approach to project design and planning. The MBS antibody development plan focuses on the timely generation of data from large fusion screens that allow for the identification of quality antibody candidates. A rigorous set of innovative and thorough screening tools are creatively developed and executed to meet dynamic customer goals with data-driven decision making. If the goals of a project change during the course of development, MBS will use accumulated data to efficiently shift focus to meet the new goals. Our mission is to use these strategies to go beyond limited contract services and be a comprehensive partner in antibody and assay method development. MBS saves customers money and compresses timelines of the most complex projects.
MBS Technical Team
Dr. Joseph Chandler: Founder and President
With deep expertise and broad experience in antibody development, Dr. Chandler founded Maine Biotechnology Services in 1990 and has overseen its growth from a small hybridoma development laboratory, to the full-service antibody partner it is today. As President, Dr. Chandler continues to lend technical expertise and serves as the managerial and business development leader of MBS.
Dr. Stephen Pelsue: Science Director
Dr. Pelsue provides technical expertise and leadership to our scientific team as they develop comprehensive strategies and project plans for antibody development. He also works to develop and integrate new tools, technologies, and processes that enhance our ability to address challenging new antibody targets on behalf of our client base. Prior to joining MBS, Dr. Pelsue was an Associate Professor of Immunology & Molecular Biology at the University of Southern Maine, where he ran a research program investigating the development of autoantibodies in autoimmune diseases.
Dr. Jennifer Walker: Hybridoma Project Manager
Dr. Walker is responsible for the management and execution of customer project plans, as well as analyzing and communicating data to facilitate timely, goal-driven decision making throughout the hybridoma development process. Prior to joining MBS, Dr. Walker was a doctoral candidate and research associate at the University of Maine focusing on B cell development, protein biochemistry, and cell signaling aberrations that permit the survival and development of autoimmune B cells.
Cheryl Steenstra: Program Manager for Custom Services
Cheryl is the translational bridge between our customers and the sales and marketing team within MBS. She is responsible for identifying opportunities to add technical value to standard project proposals through the implementation of custom services and processes. Cheryl guides the overall direction, coordination, implementation, and execution of projects that flow through the various technical labs at MBS, ensuring consistency with program strategy and commitment to meeting the project goals.
Moria Reno: Immunochemistry Lab Manager
With over 15 years of experience at MBS, Moira oversees daily operations of the Cell Culture and Immunochemistry Labs. She schedules productions, manages the workforce, and communicates with customers to allow for seamless project progression. Her coordination between customers, laboratory scientists, sales, and QA ensures timely production and release of antibodies.
Melissa Hamel: Research Scientist
Melissa developed and remains the lead scientist for the recombinant antigen expression lab at MBS. Melissa is integral to process and method development at MBS, working to optimize current services, as well as implement new services to meet customer project goals.